Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Interest Expenses (2016 - 2025)

United Therapeutics' Interest Expenses history spans 17 years, with the latest figure at $3.1 million for Q4 2025.

  • For Q4 2025, Interest Expenses fell 60.76% year-over-year to $3.1 million; the TTM value through Dec 2025 reached $19.5 million, down 54.55%, while the annual FY2025 figure was $19.5 million, 54.55% down from the prior year.
  • Interest Expenses for Q4 2025 was $3.1 million at United Therapeutics, up from $3.0 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $15.6 million in Q3 2023 and bottomed at $3.0 million in Q3 2025.
  • The 5-year median for Interest Expenses is $7.6 million (2024), against an average of $8.6 million.
  • The largest annual shift saw Interest Expenses surged 193.62% in 2023 before it tumbled 70.3% in 2025.
  • A 5-year view of Interest Expenses shows it stood at $4.7 million in 2021, then skyrocketed by 161.7% to $12.3 million in 2022, then rose by 22.76% to $15.1 million in 2023, then tumbled by 47.68% to $7.9 million in 2024, then tumbled by 60.76% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Interest Expenses are $3.1 million (Q4 2025), $3.0 million (Q3 2025), and $7.3 million (Q2 2025).